Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma
Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma
复制标题
DOI：
10.1007/s10147-006-0566-5
复制
发表时间：
2006-04
影响因子：
3.3
通讯作者：
Shinji Tanaka;S. Arii
中科院分区：
文献类型：
--
作者：
Shinji Tanaka;S. Arii
肝细胞癌（HCC）是一种典型的血管生成性肿瘤，尤其是中、低分化型。这些临床病理特征不仅对影像学诊断有帮助，而且对肝癌的治疗也有指导意义。此外，最近的分子研究表明，血管生成与肝癌的发生密切相关。本文就肝癌血管生成的分子机制及抗血管生成治疗的研究进展作一综述，并介绍抗血管生成治疗肝癌的最新进展。
Hepatocellular carcinoma (HCC) is well known as a typical angiogenic tumor, especially in the moderately to poorly differentiated type. Such clinicopathological characteristics are not only useful for imaging diagnosis but are also applicable to the treatment of HCC. In addition, recent molecular studies have revealed that angiogenesis is closely related to hepatocarcinogenesis. In this review, the molecular mechanism of HCC angiogenesis and the antiangiogenic prevention of HCC are reviewed to introduce the latest trends in antiangiogenic treatment of cancers, including HCC.